CHALLENGES TO INDIAN BIOTECHNOLOGICAL RESEARCH AND INDUSTRIES. AJINDER AND SWATI 8013 ,8011 MSC.BIOTECHNOLOGY
Contents Biotechnology and India Indian market SWOT analysis Challenges faced Biotech business in India Ipr &biotech industry Future of Indian biotech sector
BIOTECHNOLOGY AND INDIA Quite nascent stage. Biodiversity of India is an advantage for biotech sector. Over 300 registered biotech companies, out of which 100 are in modern biotech sector. 12th most successful biotech sector in world, 3rd largest in Asia with 96 enterprises(after Australia and china).
INDIAN BIOTECH MARKET Total biotech sectors: $420 million in 2002-03. Vaccines : bharat biotech, shanta biotech,pfizer, panacea,etc. Therapeutics : biocon, eli lily, etc. Diagnostics : span diagnostics,j.mitra, xcyton
SWOT ANALYSIS Strength, weakness , opportunity, threats, Best way to make critical analysis of scientific research in country.
STRENGTH: Human Resource: Trained manpower and knowledge base. •Academic Resource: Good network of research laboratories. •Industry Base: Well developed base industries (e.g. pharmaceuticals, seeds). •International Experts: Access to intellectual resources of NRI’s in this area. •Clinical Capability: Extensive clinical trials and research access to vast and diverse disease in the huge population. •Bio-diversity: India’s human gene pools and unique plant, animal & microbial diversity offer an exciting opportunity for genomic research. •Stem Cells Research: Several labs have commenced research in stem cells and have valuable stem cell lines.
Weakness Indian Biotechnology: Weakness Missing link between research and commercialization •Lack of venture capital •Relatively low R&D expenditure by industry •Image of Indian industry –doubts about ability of Indian products to meet International standards of quality
Opportunities indian Biotechnology: Opportunities •Large domestic market •Large export potential •Low cost research base for international companies in comparison with other countries •Vast and diverse disease based patient populations provide unique opportunities for clinical research and clinical trials •Supportive Government policy on embryonic stem cells research provides a useful opportunity for International companies to pursue such research in India •Human bio-diversity provides unique research opportunity in genomics •Plant & microbial bio-diversity provides vast prospecting opportunities for new drugs •Conducive Government policy on GM crops provides useful opportunities for Agri-biotech companies
Threats Exodus of brilliant brain to other countries. Enhanced level of politics in system. Improper utilization of enormous funds. Lack of scientific responsibility among young scientist.
Challenges faced by indian biotechnological sector Weak entrepreneurial skills Lack of quality human resource Lack of public private partnership. Risk averse nature of industry. Lack of venture funding
Lack of ignition grant system. Streamlining the regulatory process. Time to market. Poor feasibility of indian market. Partnership with pharmaceutical industry.
Business in india Joint venture Collaborative research. Contract research Technology transfer Clinical research.
IPR and the Biotech Industry Ipr importance •IP is a central issue in any industry •Robust intellectual property rights framework is the need of the hour •India is already member of –Paris Convention –PCT –Berne Convention –Convention on biological diversity –WTO •Should make legislation clear on the criteria for the patentability of biotechnological inventions
Ipr scenario in India(challenges): need to improve patent legislation infrastructure needs attention till 2005 only process were granted patent. poor patent protection & litigation attracts less foreign ventures. inefficient indian judicial system.
What can be Claimed? –Diagnostic tests –Research tools –Gene therapy –Therapeutic proteins Sensors –Bioinformatics –Sequences –Pharmaceuticals
The future of Biotechnology •Developing diverse, collaborative relationships to strengthen its industry •Harmonizing standards with international standards in manufacturing and laboratory practices (ensuring foreign markets and enhancement of the industry’s global and local standing) •Cheaper labor, technical capacity and expertise may capture markets away from companies in the developed countries •Illustrates the importance of fostering a regulatory and IP environment (encouraging innovative startup companies)